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OBJECTIVE — Bimodalityinthedistributionofglucosehasbeenusedtodeﬁnethecutpoint
for the diagnosis of diabetes. Previous studies on bimodality have primarily been in populations
with a high prevalence of type 2 diabetes, including one study in a white Caucasian population.
All studies included participants with known diabetes. The aim of this study was to assess
whether a bimodal structure is a general phenomenon in fasting plasma glucose (FPG) and 2-h
plasma glucose that is useful for deriving a common cut point for diabetes in populations of
different origin, both including and excluding known diabetes.
RESEARCH DESIGN AND METHODS — The Evaluation of Screening and Early De-
tectionStrategiesforType2DiabetesandImpairedGlucoseTolerance(DETECT-2)projectisan
internationalcollaborationpoolingsurveysfromallcontinents.Thesestudiesincludesurveysin
which plasma glucose was measured during an oral glucose tolerance test; in total, 43 studies
(135,383 participants) from 27 countries were included. A mixture of two normal distributions
was ﬁtted to plasma glucose levels, and a cut point for normal glycemia was estimated as their
intersection. In populations with a biologically meaningful cut point, bimodality was tested for
signiﬁcance.
RESULTS — Distributions of FPG and 2-h plasma glucose did not, in general, produce bi-
modal structures useful for deriving cut points for diabetes. When present, the cut points
produced were inconsistent over geographical regions.
CONCLUSIONS — Deriving cut points for normal glycemia from distributions of FPG and
2-hplasmaglucosedoesnotappeartobesuitablefordeﬁningdiagnosticcutpointsfordiabetes.
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B
imodality in glucose distribution
has been reported in a number of
populations with a high prevalence
of diabetes, including the American Pima
Indians (1) and the Micronesian popula-
tionofNauru(2).Thisobservationwasan
important component in deﬁning the
1980WorldHealthOrganization(WHO)
diagnostic criteria for diabetes together
with thresholds for diabetes-speciﬁc
microvascular complications such as
retinopathy. Subsequent studies of
bimodality in Egypt (3,4) and in Mexican
Americans (5) rendered further support
for the WHO 1980 and 1985 diagnostic
criteria for diabetes (6,7).
Later, the presence of bimodality in
glucose was also found in the high-
diabetes-prevalencepopulationsinPapua
New Guinea (8) and in South African In-
dians(9).Fewstudiesonbimodalityhave
been conducted in populations with low
diabetesprevalence(10–12).Here,bimo-
dality was shown in 2-h plasma glucose
values but with differing cut points for
normal glycemia. Only one study has
demonstratedbimodalityinwhiteCauca-
sians (13).
These ﬁndings in diverse populations
suggest that bimodality in glucose is uni-
versal. However, all of these studies in-
cluded participants with known diabetes.
Patientswithdiabetesaretreated(lifestyle
and medication) to lower glycemic levels.
Includingthesepatientsintheanalysisin-
troduces a systematic treatment bias,
something that could either enhance or
diminish the bimodal structure of data.
The aim of this study was to assess
whether distributions of plasma glucose
(fasting and 2 h), in general, give rise to a
bimodal structure, which is useful for de-
riving a cut point for diabetes in popula-
tions of different origin, both including
and excluding participants with known
diabetes and, if present, to assess whether
the cut point for normal glycemia derived
from such a bimodal structure varied be-
tween populations from different geo-
graphic regions.
RESEARCH DESIGN AND
METHODS— This study is based on
the Evaluation of Screening and Early De-
tection Strategies for Type 2 Diabetes and
ImpairedGlucoseTolerance(DETECT-2)
database,aworldwidecollaborativestudy
based on original data from population-
based surveys of 500 participants (14).
The individual studies have been de-
scribed precisely (supplemental data,
available in an online appendix at http://
dx.doi.org/10.2337/dc08-0867). In this
analysis, only studies in which plasma
glucose was measured during a 75-g oral
glucose tolerance test were included.
Participants who had been told by a
doctor they had diabetes or who were re-
ceiving antidiabetes treatment (diet or
medication) were deﬁned as having
knowndiabetes.Allotherswereclassiﬁed
according to the WHO 1999 diagnostic
criteria (15). Participants with one glu-
cose value in the nondiabetic range and
missing data for the other glucose value
could not be classiﬁed according to the
WHO criteria and were excluded. All
analyses were performed ﬁrst excluding
and then including participants with
known diabetes. In all surveys, partici-
pants gave their consent for participation
in accordance with the Declaration of
Helsinki.
Statistical methods
Analyses were performed using R version
2.8.0. All analyses were stratiﬁed by
country.
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glucose (FPG) and 2-h plasma glucose are
skewed to the right. To reduce skewness,
glucose values were log transformed before
model ﬁtting. A normal distribution and a
mixture of two normal distributions were
ﬁtted to the log-transformed glucose data.
The probability density function for the
normal distribution is as follows:
fx; ,  
1
2
exp
x  
2
2
2 .
Here,  and  are the mean and SD of x.
We ﬁtted the normal distribution to data
using the maximum likelihood method.
The probability density function for the
mixture model of two normal compo-
nents is as follows:
Table 1—Characteristics of the study populations
Region Country Center n
Known
diabetes (%) SDM (%) Age range Study period
Greenland Greenland B99* 1,142 1.1 9.1 27–86 1998–2002
North Europe U.K. Ely* 1,156 — 7.0 40–69 1990–1992
NHP* 800 2.6 7.6 30–76 1992–1994
Whitehall II 10,270 0.8 1.5 39–63 1991–1993
Finland East-West Finland* 461 12.4 10.8 70–89 1989
FIN–MONICA92 1,929 4.6 3.9 40–64 1992
Vantaa* 613 11.3 6.4 64–66 1990–1991
FINRISK02* 3,767 3.3 8.8 44–75 2002
Sweden NSW–MONICA 3,561 6.8 2.8 25–75 1986–2004
ULSAM*† 1,221 5.7 10.3 69–74 1991–1995
Denmark Glostrup* 695 5.6 3.7 59–62 1996–1997
Inter99* 6,784 2.0 3.9 30–60 1999–2001
Germany KORA* 1,485 8.8 8.0 55–74 1999–2001
Central Europe Holland Hoorn* 2,484 3.5 6.6 49–77 1989–1991
Zutphen* 484 8.1 9.7 70–90 1990
France Paris Prospective* 7,176 2.0 4.3 44–55 1968–1974
Poland PMSDE* 2,838 6.3 7.8 35–77 1998–2000
South Europe Spain Guia* 693 8.9 9.7 30–93 1994–1997
Israel GOH*† 1,291 1.9 7.3 35–69 1976–1982
Eastern Mediterranean and Middle East Egypt Egypt*† 1,451 28.5 9.3 20–89 1992–1993
Africa Mauritius Mauritius* 4,908 6.1 8.4 25–75 1987
Cameroon Cameroon* 1,804 0.4 0.7 24–74 1996
India India CUPS*† 1,259 7.1 4.8 20–87 1996–1998
Dombivli 550 5.5 8.5 31–80 1998–1999
Chennai† 2,182 7.5 6.4 18–94 1993–1995
CURES* 2,350 6.1 9.7 20 2001–2004
Japan Japan Funagata*† 2,154 5.1 3.5 35–89 1992–1997
Asia remaining China Harbin† 1,376 1.5 2.0 40–85 1998
Qingdao 2,061 4.7 9.3 30–74 2002
Indonesia Jakarta*† 1,019 3.5 4.3 14–87 1992–1993
Taiwan Kinmen* 1,456 — 12.6 30–88 1991–1994
Singapore NHS92* 3,568 4.4 6.0 17–69 1992
Korea Korea 10,044 5.7 7.3 37–71 2001–2003
Vietnam Vietnam* 9,122 1.2 2.3 30–65 2002
Australia and New Zealand Australia AusDiab* 11,144 5.1 4.2 25–95 1999–2000
Paciﬁc Islands Nauru Nauru* 868 19.1 14.7 19–81 1987
Tonga Tonga* 472 — 15.0 15–85 1998–2000
Tonga04* 1,016 — 9.3 15–87 2001–2004
Samoa Samoa* 3,285 3.8 7.5 20–90 1978–1991
North America U.S. NHANES III*† 3,105 7.1 9.9 40–74 1988–1994
NHANES II*† 3,814 2.6 5.6 20–74 1976–1980
ARIC, U.S.* 11,596 11.8 10.0 52–70 1996–1999
NHANES99* 5,929 4.8 2.6 12–85 1999–2001
*Centerswithmeasuredfastingplasmaglucoseinindividualswithknowndiabetes.†Centerswithmeasured2-hplasmaglucoseinindividualswithknowndiabetes.
‡InNHANES99,SDMisbasedonfastingvaluesonly.ARIC,AtherosclerosisRiskinCommunities;AusDiab,AustralianDiabetes,ObesityandLifestyleStudy;CUPS,
Chennai Urban Population Study; CURES, Chennai Urban Rural Epidemiology Study; FIN-MONICA, Finland Monitoring of Trends and Determinants in Cardio-
vascularDisease;GOH,GlucoseIntoleranceObesityandHypertension;FINRISK02,FINRISK2002;KORA,CooperativeHealthResearchintheRegionofAugsburg;
NHANES, National Health and Nutrition Examination Survey; NHS92, 1992 National Health Survey; NHP, Newcastle Heart Project; NSW-MONICA, New South
WalesMonitoringofTrendsandDeterminantsinCardiovascularDisease;PMSDE,PolishMulticenterStudyonDiabetesEpidemiology;ULSAM,LongitudinalStudy
of Adult Men.
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Here,  and 1 are the mixture pro-
portions with  between zero and unity.
The mixture model was ﬁtted using a
combination of a Newton-type method
and the expectation-maximization (EM)
algorithm (16) (the normalmixEM2comp
functionfromtheMixtoolspackageinR).
To assess the presence of bimodality,
the mixture model was compared with
the unimodal distribution. The variance
of the two components in the mixture
model may differ. In that case, simulation
results have shown that the limiting func-
tion for the likelihood ratio test is
bounded by 	
2 distributions with 4 and 6
degrees of freedom (d.f.) (17). In this
study,Pvaluesforsigniﬁcanceofthemix-
ture model were based on a 	
2 distribu-
tion with 4 d.f. A signiﬁcance level of 5%
was used.
A cut point for normal glycemia was
calculatedasthecrossingpointofthetwo
normal distributions in the mixture
model. Approximate CIs for the cut
points were estimated by bootstrapping
(1,000 bootstraps) (18).
The aim of this study was to detect
whether distributions of FPG and 2-h
plasma glucose give two distinct entities
that may be used to separate individuals
into two groups: those having normal or
abnormal glycemia. For this separation to
be biologically meaningful, the cut point
separating these two entities should be
between their modes (1, 2). If not, the
estimated cut point would not be useful
because more than half of the individuals
in the upper entity would have a glucose
level below the cut point, which, conse-
quently, would identify them as having
normal glycemia.
Mixturemodelswereﬁttedtotheglu-
cose values in each country to derive cut
points for normal glycemia. In countries
in which this cut point was biologically
meaningful, the presence of bimodality
was tested. As described in an earlier
study on bimodality (10), the ability of a
ﬁtted mixture model to be statistically su-
perior to a unimodal model depends on
the sample size, the prevalence of diabe-
tes, and the difference between the means
of the two underlying distributions in
units of SDs. In small samples, a lack of
power may prohibit signiﬁcance of the
mixture model even when bimodality is
truly present. To not be limited by lack of
power, all biologically meaningful cut
points for normal glycemia are reported
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signiﬁcance of the mixture model.
RESULTS— This study included
135,383 participants with measurements
of FPG and/or 2-h plasma glucose from
43 studies in 27 different countries cov-
ering 12 different geographic regions. Ta-
ble 1 lists the characteristics of the study
populations.
The prevalence of screen-detected di-
abetes (SDM) ranged from 0.7% in Cam-
eroon to 14.7% in Nauru. Analysis was
done by country, pooling the individual
studies within a country. Because the in-
dividual studies varied in both sex and
age distribution, the pooled data for a
country do not necessarily reﬂect the age
and sex distribution in that country. Indi-
vidual records have not been weighted in
the analyses.
The proportion of men and the age
range varied among the countries. In
studiesincludingbothsexes,menseemed
slightly underrepresented. The Dutch
and German studies were the oldest
(49–89 and 55–74 years, respectively),
whereas the French study was restricted
to the middle-aged (44–55 years) popu-
lation. In the remaining countries, age
range was well represented. In all coun-
tries, prevalence of diabetes increased
with age, with the only exception being
Samoa, where a small decrease was
observed.
Analyses excluding patients with
known diabetes
For FPG, the mixture model resulted in a
biologically meaningful cut point for nor-
mal glycemia in 5 of 27 countries (19%).
Except for Singapore, the mixture model
was also statistically superior to the uni-
modalmodel;i.e.,bimodalitywaspresent
(Table 2). The estimated cut points
ranged from 6.1 mmol/l (95% CI 6.0–
6.3) in Korea to 7.2 mmol/l (6.8–7.6) in
Nauru (Fig. 1). Pooling the ﬁve meaning-
ful cut points, the overall cut point for
normal glycemia was estimated to be 6.7
mmol/l (6.5–6.9) (Fig. 2). This result is
somewhat lower than the WHO diabetes
diagnostic cut point for fasting plasma
glucose of 7.0 mmol/l. Removing Singa-
pore (where bimodality was not signiﬁ-
cant) from the pooled analysis decreased
the overall estimated cut point by 0.2
mmol/l.
For2-hplasmaglucose,8of26coun-
tries (30%) produced a meaningful cut
point. Except for Sweden, Spain, and
Tonga,themixturemodelwasstatistically
superior (Table 2). The estimated cut
points ranged from 8.5 mmol/l (95% CI
7.6–9.5) in Egypt to 12.7 mmol/l (7.6–
14.9) in Taiwan (Fig. 1). The overall cut
point was 11.0 mmol/l (10.6–11.4) (Fig.
2). This result corresponds to the WHO
diabetes diagnostic cut point for 2-h
plasmaglucoseof11.1mmol/l.Removing
Sweden, Spain, and Tonga from the
pooled analysis decreased the overall es-
timated cut point by 0.2 mmol/l.
Analyses including patients with
known diabetes
All countries except two had measure-
ments of FPG in participants with known
diabetes (n  103,410). Repeating the
analyses for FPG including patients with
knowndiabetes,11of25countries(44%)
now produced a meaningful cut point. In
only one of these 11 countries (Singa-
pore) was the mixture model not statisti-
cally superior to the unimodal model
(Table 2). The pooled cut point was 6.8
mmol/l (95% CI 6.7–6.8) both with and
Figure 1—Distribution of FPG in Korea (A) and Nauru (B) and 2-h plasma glucose in Egypt (C) and Taiwan (D). Patients with known diabetes
areexcluded.Thehistogramsrepresentdata(intervalsof0.2mmol/l).Thesuperimposedsolidcurveistheﬁttedmixturemodel,andthedottedcurves
are the two underlying distributions.
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with the result found when patients with
known diabetes were excluded. In addi-
tion, the range in cut points was compa-
rable:from6.4mmol/l(5.9–6.7)inIndia
to 7.4 mmol/l (6.9–7.7) in Nauru.
Tenstudiesfromeightdifferentcoun-
tries had measurements of 2-h plasma
glucose in participants with known dia-
betes (n  18,872). Of these, ﬁve (63%)
produced a meaningful cut point for nor-
mal glycemia, and, in addition, the mix-
ture model was signiﬁcantly superior in
Egypt, India, and the U.S. (Table 2). The
corresponding pooled cut point was 10.9
mmol/l(95%CI8.3–11.3),whichwasre-
duced by 0.6 mmol/l when Sweden and
Japan, which had nonsigniﬁcant mixture
models, were removed from the analysis.
This result is also consistent with the re-
sult found when patients with known di-
abetes were excluded but with a greater
range in the individual cut points from
8.2 mmol/l (7.8–8.7) in India to 13.6
mmol/l (12.8–14.7) in Sweden.
CONCLUSIONS — Whenknowndi-
abeteswasexcludedfromtheanalysis,re-
sults from less than one-third of the
countries were useful for deriving a cut
pointfornormalglycemiainFPGand2-h
plasma glucose. Consequently, when
known diabetes is removed, distributions
of plasma glucose do not commonly give
rise to a bimodal structure that is useful
for deriving a cut point for diabetes. In-
clusionofparticipantswithknowndiabe-
tes, although not universally present,
more than doubled this proportion to
44%forFPGand63%for2-hplasmaglu-
cose.Inmostcountrieswithameaningful
cut point, the mixture model was signiﬁ-
cantly superior to the unimodal normal
model.Thistestwas,however,basedona
	
2 distribution with 4 d.f. to err on the
side of rejecting unimodality in favor of
bimodality.Theseresultsindicatethatthe
presence of a biologically meaningful bi-
modal structure in glucose seems to be
driven by patients with known diabetes.
The overall pooled cut points for nor-
mal glycemia were almost invariant to
whether or not participants with known
diabetes were included. However, the es-
timated cut points were inconsistent be-
tweencountries,especiallyfor2-hplasma
glucose when participants with known
diabetes were included. Comparing these
results with those of earlier studies, we
found that the overall cut point for FPG
was somewhat lower (2,3,8,9), whereas
the cut point for 2-h plasma glucose was
wellinline(1–3,5,8,10,11,13),exceptfor
the studies of South African Indians (9)
and Western Samoans (12), which pro-
duced lower cut points for 2-h plasma
glucose.
Earlier studies reported that bimodal
structure in glucose distribution is more
pronounced in the older age-groups, in
whomtheprevalenceofdiabetesishigher
(1,2,5,8,9,11,12). We addressed the pos-
sible effect of age by considering the sub-
population aged 60 years (data not
shown). In general, our main results were
reproduced in this age-group. Only very
few additional countries produced a bio-
logically meaningful cut point, but again,
including patients with known diabetes
increased the proportion of meaningful
bimodal structures. This ﬁnding is in line
withanearlierstudyshowingthemeanof
the upper normal component to be simi-
lar in different age-groups (4).
To increase sample size, we also
pooled populations that were geographi-
cally in the same ethnic area: Caucasians,
Africans, Asians, and Paciﬁc Islanders
(data not shown). A meaningful bimodal
structure of data was only detected in half
of the ethnic areas.
Excluding participants with known
diabetes from the analyses reduces the
prevalence of diabetes in the population
by 50%, which may prohibit a signiﬁ-
cant ﬁt of the mixture model. In addition,
Figure2—Cutpoints(95%CI)fornormalglycemiainglucose.Thegrayandblacklinesrepresentanalyseswithandwithoutindividualswithknown
diabetes. The dotted vertical line is the WHO 1999 cut point for diabetes. *Statistically signiﬁcant mixture model.
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likely to be lower when patients with
knowndiabetesthatismoreadvancedare
excluded. This exclusion potentially
makes the two components less distinct
and thereby decreases the probability of a
meaningful cut point separating them.
However, as acknowledged in previous
studies (3,10,13), including patients with
known diabetes in the analyses will in-
duce a treatment bias for the following
reasons.Inaccordancewithexistingtreat-
ment guidelines, patients with diabetes
are treated with the aim of lowering their
glucose to a near-normal range. This im-
plies that diabetic patients with higher
glucose values are treated relatively more
aggressively than patients with only
slightly raised glucose values. It seems
reasonable to assume that aggressively
treated patients have a larger absolute de-
creaseinglucosevaluesthanpatientswho
are treated less aggressively (19). There-
fore,theeffectoftreatmentisnotanequal
shift to the left in the glucose distribution
of the entire diagnosed population but,
rather, a shift that increases with glucose
values at diagnosis (20). Hence, the glu-
cosevaluesofthesubgroupwiththehigh-
est values is shifted toward the glucose
values of the rest of the diagnosed popu-
lation. This means that patients with di-
agnosed diabetes are bunched together,
thereby potentially creating an artiﬁcial
bimodal structure in the glucose data.
How do we overcome this problem?
The ideal setting for studying bimodality
in glucose distribution is a treatment-
naive population (including diabetes
treatment) in whom diabetes is undiag-
nosed. This is not the case in any of the
studiesinthisanalysis.Atheoreticalsolu-
tion to the problem is to adjust the mea-
sured glucose value of a treated patient to
its untreated level. This would require
knowledgeoftheexacteffectoftreatment
for each patient. However, different doc-
tors may prescribe different treatments to
patients with the same glucose levels. In
addition,evenifthesametreatmentisad-
ministered, its effect will vary among pa-
tientsbecauseofdifferencesinphenotype
as well as in adherence to treatment.
Hence, adjusted glucose values are highly
uncertain. A study from Malaysia (10)
suggestedimputingglucosevaluesforthe
patients with known diabetes using the
measured glucose values of the partici-
pants with SDM in the same population
and taking into account age, sex, ethnic-
ity,andmedicalhistoryofdiabetesstatus.
The model does not account for diabetes
duration. However, glucose is known to
increase with diabetes duration despite
increasing treatment (21). Participants
with SDM have, by deﬁnition, newly di-
agnosed diabetes, whereas patients with
known diabetes may have had the diag-
nosis several years previously, which
questions the validity of imputing their
glucose values based on those of partici-
pants with SDM.
In summary, this study has shown
that distributions of FPG and 2-h plasma
glucose, in general, do not give rise to a
bimodal structure that is useful for deriv-
ingacutpointfordiabetesinpopulations
of different origin. Including patients
with known diabetes increases the possi-
bility of deriving a meaningful cut point,
but the bimodal structure in data may be
a treatment artifact. In addition, cut
points produced for normal glycemia
were inconsistent over geographical re-
gions. Thus, bimodality is not a suitable
method for deﬁning diagnostic cut points
for diabetes. Instead, it seems more rele-
vant to base the diagnostic criteria on
thresholds for diabetes-speciﬁc micro-
and macrovascular complications. How-
ever, further analyses are needed in this
area.
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